BackCompass Therapeutics Overview

Compass Therapeutics Long Term Debt

Track Compass Therapeutics's long-term debt ($8M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$8.00M
↓ 16.99% YoYΔ $-1.64M vs prior year quarter

Peer trimmed avg / median

Loading

Compass Therapeutics Long Term Debt History

Loading

Compass Therapeutics vs. peers: Long Term Debt Comparison

Loading

Compass Therapeutics Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Compass Therapeutics (CMPX) FAQ

As of the most recent data (June 2026), CMPX shows a long-term debt of $8M. That compares with $9.6M in the prior-year period — down 17.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CMPX's long-term debt is now $8M (was $9.6M) — a 17.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Compass Therapeutics is outperforming or lagging.

Tracking CMPX's long-term debt over time shows whether Compass Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $8M That compares with $9.6M in the prior-year period — down 17.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Compass Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $8M) with ownership activity and broader fundamentals.

Compass Therapeutics's long-term debt is $8M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.